• Levulan® Kerastick®  
  (aminolevulinic acid HCl)
  for Topical Solution, 20%
  Levulan® Kerastick®Levulan® Kerastick® plus blue light illumination using the BLU-U® blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2) of the face or scalp.
  
  Learn More >>
• BLU-U®  
  Blue Light Photodynamic TherapyIlluminator
  Model 4170
  BLU-U®The BLU-U is a unique blue light that can kill the P. acnes bacteria in your skin.
  
  Learn More >>
• ClindaReach®  
  (Clindamycin Phosphate Topical Solution USP, 1%)
  Pledgets
  ClindaReach®ClindaReach is indicated for the topical treatment of acne vulgaris and is only available by prescription.
  
  Learn More >>

News

February 2, 2010
DUSA Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

November 10, 2009
Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period

November 6, 2009
DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

Welcome

DUSA Pharmaceuticals, Inc.® is an integrated dermatology pharmaceutical company committed to improving people's health and confidence through its quality dermatological treatments. DUSA markets and continues to develop its Levulan® Photodynamic Therapy (PDT) technology platform, which is a treatment for the pre-cancerous skin lesions known as Actinic Keratoses (AK). DUSA is also developing certain internal indications of Levulan PDT.

DUSA's portfolio of complementary dermatology products includes ClindaReach®, which was acquired from Sirius Laboratories, Inc. ClindaReach is a topical acne treatment which includes a novel applicator for those hard-to-reach areas.